Cholesterol levels in Fragile X syndrome

American Journal of Medical Genetics, Part A

Volumn 167, Issue 2, 2015, Pages 379-384

  Berry Kravis, Elizabeth ^a   Levin, Rebecca ^a   Shah, Haroon ^a   Mathur, Shaguna ^a   Darnell, Jennifer C ^b   Ouyang, Bichun ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Cholesterol; FMR1; FMRP; Fragile X syndrome; HDL; LDL; Lovastatin

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; CHOLESTEROL;

ADOLESCENT; ADULT; AFRICAN AMERICAN; ARTICLE; ASIAN; CAUCASIAN; CHILD; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION COEFFICIENT; ETHNICITY; FEMALE; FRAGILE X SYNDROME; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NATIONAL HEALTH SERVICE; PATIENT MONITORING; RACE DIFFERENCE; SEX DIFFERENCE; SYSTEMATIC REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; PRESCHOOL CHILD; RISK FACTOR; YOUNG ADULT;

ANIMALIA;

ADULT; CHILD, PRESCHOOL; CHOLESTEROL; FEMALE; FRAGILE X SYNDROME; HUMANS; MALE; RISK FACTORS; YOUNG ADULT;

EID: 84921416908     PISSN: 15524825     EISSN: 15524833     Source Type: Journal    
DOI: 10.1002/ajmg.a.36850     Document Type: Article

References (24)

1. Abbasi F, Blasey C, Reaven G. 2013. Cardiometabolic risk factors and obesity: Does it matter whether BMI or waist circumference is the index of obesity?. Am J Clin Nutr 98:637-640.
2. Alcobra Ltd, A 6-week, Study of MG01CI Low Dose and High Dose Compared With Placebo in Adults and Adolescents With Fragile X Syndrome. 7 http://www.clinicaltrials.gov/ct2/show/NCT02126995?term.
3. Bennasar-Veny M, Lopez-Gonzalez A, Tauler P, Cespedes M, Vicente-Herrero T, Yanez A, Tomas-Salva M, Aguilo A. 2013. Body adiposity index and cardiovascular health risk factors in Caucasians: A comparison with the body mass index and others. PLoS One 8:e63999.
4. Berry-Kravis E, Hessl D, Abbeduto L, Reiss A, Beckel-Mitchener A, Urv T. 2013. Outcome measures for clinical trials in Fragile X syndrome. J Dev Behav Pediatr 34:508-522.
5. Berry-Kravis E, Knox A, Hervey C. 2011. Targeted treatments for fragile X syndrome. J Neurodevelop Disord 3:193-210.
6. Boekholdt SM, Arsenault BJ, Hovingh GK, Mora S, Pedersen TS, Larosa JC, Welch KM, Amarenco P, Demicco DA, Tonkin AM, Sullivan DR, Kirby A, Colhoun HM, Hitman GA, Betteridge DJ, Durrington PN, Clearfield MB, Downs JR, Gotto AM Jr, Ridger PM, Kastelein JJ. 2013. Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: A meta-analysis. Circulation 128:1504-1512.
7. Bregman J, Leckman J, Ort S. 1990. Thyroid function in Fragile-X syndrome males. Yale J Biol Med 63:293-299.
8. Crawford D, Acuna J, Sherman S. 2001. FMR1 and the fragile X syndrome: human genome epidemiology review. Genet Med 3:359-371.
9. Darnell J, Klann E. 2013. The translation of translational control by FMRP: Therapeutic targets for FXS. J Nat Neurosci 16:1530-1536.
10. Darnell J, Van Driesche S, Zhang C, Hung K, Mele A, Fraser C, Stone E, Chen C, Fak J, Chi S, Licatalosi D, Richter J, Darnell R. 2011. FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and Autism. Cell 146:247-261.
11. Global Lipids Genetics Consortium. 2013. Discovery and refinement of loci associated with lipid levels. Nat Genet 45:1274-1282.
12. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Judd SE, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Mackey RH, Magid DJ, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER 3rd, Moy CS, Mussolino ME, Neumar RW, Nichol G, Pandey DK, Paynter NP, Reeves MJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Wong ND, Woo D, Turner MB, American Heart Association Statistics Committee, Stroke Statistics Subcommittee. 2014. Executive Summary: Heart Disease and Stroke Statistics-2014 Update: A Report From the American Heart Association. Circulation 129:399-410.
13. Gross C, Berry-Kravis E, Bassell G. 2012. Therapeutic strategies in fragile X syndrome: Dysregulated mGluR signaling and beyond. Neuropsychopharmacology 37:178-195.
14. Grossman A, Berry-Kravis E, Crnic L, Greenough W. 2002. Understanding fragile X mental retardation syndrome. Curr Pediatr 12:316-324.
15. Hagerman R, Berry-Kravis E, Kaufmann W, Ono M, Tartaglia N, Lachiewicz A, Kronk R, Delahunty C, Hessl D, Visootsak J, Picker J, Gane L, Tranfaglia M. 2009. Advances in the treatment of Fragile X syndrome. Pediatrics 123:378-390.
16. Hickman T, Briefel R, Carroll M, Rifkind B, Cleeman J, Maurer K, Johnson C. 1998. Distributions and trends of serum lipid levels among United States children and adolescents ages 4-19 years: Data from the Third National Health and Nutrition Examination Survey. Prev Med 27:879-890.
17. Moses L, Katz N, Weizman A. 2013. Metabolic profiles in adults with autism spectrum disorder and intellectual disabilities. Eur Psychiatry 924-9338 0-00071 10.1016/j.eurpsy.2013.05.005.
18. Ogden CL, Carroll MD, Kit BK, Flegal KM. 2012. Prevalence of childhood and adult obesity in the United States, 2011-2014. JAMA 311: 806-814.
19. Osterweil E, Chuang S, Chubykin A, Sidorov M, Bianchi R, Wong R, Bear M. 2013. Lovastatin corrects excess protein synthesis and prevents Epileptogenesis in a mouse model of Fragile X syndrome. Neuron 77:243-250.
20. Pieretti M, Zhang F, Fu Y, Warren S, Oostra B, Caskey C, Nelson D. 1991. Absence of expression of the FMR-1 gene in Fragile X syndrome. Cell 66:817-822.
21. Qin M, Smith C. 2008. Unaltered hormonal response to stress in a mouse model of Fragile X syndrome. Psychoneuroendocrinology 33:883-889.
22. Utari A, Adams E, Berry-Kravis E, Chavez A, Scaggs F, Ngotran L, Boyd A, Hessl D, Gane L, Tassone F, Tartaglia N, Leehey M, Hagerman R. 2010. Aging in Fragile X syndrome. J Neurodevelop Disord 2:70-76.
23. Werner H, Kramer-Albers E, Strenzke N, Saher G, Tenzer S, Ohno-Iwashita Y, De Monasterio-Schrader P, Mobius W, Moser T, Griffiths I, Nave K. 2013. A critical role for cholesterol-associated proteolipids PLP and M6B in myelination of the central nervous system. GLIA 61:567-586.
24. Wilson D, Carpenter N, Berkovitz G. 1988. Thyroid function in men with Fragile X-linked MR. Am J Med Genet 31:733-734.